A study to compare the safety and efficacy of BIIB033 to a placebo in patients with first episode of loss of vision due to acute inflammation in the optic nerve
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis
What was tested
Treatment tested
- Opicinumab
Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitor
What it measured
Main measures
Primary Efficacy Endpoint: Change in optic nerve conduction velocity (NCV) at Week 24 for the affected eye from the baseline of unaffected fellow eye as determined by full-field visual evoked potential (FF-VEP).
Myelin repair
Other measures (1)
Secondary Efficacy Endpoint:
Loading reviews and guidelines…
Related trials
- ReCOVER
Phase 2 · Recruiting
Still running
- RENEWED
Phase 2 · Completed
Missed its main goal
- BIIB033 In Acute Optic Neuritis (AON)
Phase 2 · Completed
Missed its main goal
History
- In scope changed from true to false
Started
Aug 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error